| 标题 |
Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer |
| 网址 | |
| DOI | |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)